Marco Timmers, PhD | CEO, Byondis
Marco has served as Chief Executive Officer (CEO) of Byondis since November 2019.
Prior to his appointment as Byondis CEO, Marco held the position of Chief Scientific Officer of Synthon Biopharmaceuticals (which later became Byondis) since it became a Synthon subsidiary in 2012. In this role, he was responsible for the development of a pipeline of new biological and chemical molecular entities, including monoclonal antibodies, antibody-drug conjugates and small molecules.
Before joining Synthon Biopharmaceuticals, Marco worked for more than 15 years at Organon, Schering-Plough and MSD. During this period, he held positions of increasing responsibility, ultimately serving as Head of Pharmacology and Site Lead for Women’s Health and Endocrinology and as a member of the R&D and Site Management teams.
Marco holds an MSc in Chemistry and a PhD in Bioorganic Chemistry, both from Leiden University, the Netherlands.
We are a clinical stage biopharmaceutical research and development company with around 400 staff, including highly educated scientists and skilled technicians who share the same goal:
To create safe and effective precision medicines targeting intractable cancers and autoimmune diseases, improving the standard of care for patients.
Powered by: Hyphen Projects | Let's connect: |
Book a ticket
| |||
FAQ Contact Us Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
|
Keep me informed
Download our event app
|
© Copyright 2023 by Hyphen Projects